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Envelope glycoproteinEffective vaccine development for human immunodeﬁciency virus type 1 (HIV-1) will require assays that
ascertain the capacity of vaccine immunogens to elicit neutralizing antibodies (NAb) to diverse HIV-1 strains.
To facilitate NAb assessment in peripheral blood mononuclear cell (PBMC)-based assays, we developed an
assay-adaptable platform based on a Renilla luciferase (LucR) expressing HIV-1 proviral backbone. LucR was
inserted into pNL4-3 DNA, preserving all viral open reading frames. The proviral genome was engineered to
facilitate expression of diverse HIV-1 env sequences, allowing analysis in an isogenic background. The
resulting Env–IMC–LucR viruses are infectious, and LucR is stably expressed over multiple replications in
PBMC. HIV-1 neutralization, targeting TZM-bl cells, was highly correlative comparing virus (LucR) and cell
(ﬁreﬂy luciferase) readouts. In PBMC, NAb activity can be analyzed either within a single or multiple cycles of
replication. These results represent advancement toward a standardizable PBMC-based neutralization assay
for assessing HIV-1 vaccine immunogen efﬁcacy.ingham, 701 19th Street South,
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An efﬁcacious vaccine against HIV-1 may require the elicitation of a
potent, broadly neutralizing antibody (NAb) response (Baba et al., 2000;
Haynes and Monteﬁori, 2006; Johnston and Fauci, 2007; Mascola et al.,
2000; McMichael, 2006; Nishimura et al., 2003; Pantophlet and Burton,
2006; Phogat et al., 2007; Plotkin, 2008; Shibata et al., 1999). The ability
to develop immunogens capable of eliciting such antibodies is integrally
linked to a requirement for standardized, high-throughput in vitro assaymeasurements that reﬂect the in vivo potency and breadth of NAb
responses elicited by natural infection or experimental vaccine
immunogens (Fenyo et al., 2009; Mascola et al., 2005b; Monteﬁori et
al., 2007; Polonis et al., 2008). It is not currently known which in vitro
assay results may correlate with antibody protection from HIV-1
infection in vivo, and several assay formats will continue to have to be
employed to assess antibody responses elicited by vaccine immunogens
(Fenyo et al., 2009; Pantophlet and Burton, 2006; Polonis et al., 2008,
2009). With support from multi-institutional HIV/AIDS vaccine initia-
tives [NeutNet (Neutralization Network) Project, CAVD/CA-VIMC,
Global HIV/AIDS Vaccine Enterprise (GHAVE), NIH Center for HIV/AIDS
Vaccine Immunology (CHAVI), and International AIDS Vaccine initiative
(IAVI)], great efforts are being invested in thediscovery, standardization
and implementation of new assay platforms for assessing breadth and
potency of neutralizing antibodies (Fenyo et al., 2009; Mascola et al.,
2005a; Monteﬁori et al., 2007; Monteﬁori, 2009; Polonis et al., 2008).
A comprehensive review of the strengths and differences between the
two most widely utilized neutralization assays, the PBMC- and the
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Fig. 1. Schematic representation of the insertion of the Renilla luciferase gene into the
NL4-3 viral backbone and the “shuttling in” of heterologous env ectodomain sequences.
The LucR gene and a T2A peptide (amino acid sequence underlined) were fused in-frame
and insertedbetween theNL4-3 env andnef genes. * indicates the co-translational cleavage
point between thepenultimate and last amino acid of T2Aand the arrow indicates the start
codon of Nef. The nt sequence is depicted for the junction between the env TAA and LucR
gene ATG. Furthermore, the “shuttling in” of heterologous env ectodomain sequences
between the viral KpnI site (NL4-3 nt 6343) and the introduced silent BstBI site (NL4-3 nt
8301) in the membrane-spanning domain is depicted.
2 T.G. Edmonds et al. / Virology 408 (2010) 1–13pseudovirion-based neutralization assays, was recently published by
Polonis et al. (Polonis et al., 2008).
Improvements in PBMC assay performance are urgently needed.
While considered to bemore physiologically relevant, the PBMC assay
is labor-intensive, expensive and not practical for high-throughput
analysis (D'Souza et al., 1997; Gauduin et al., 1996). This assay also
exhibits substantial variability owing in part to donor PBMC variability
(Polonis et al., 2009), and to the extensive use of primary virus isolates
which complicates standardization. Moreover, the assay has been
dependent on measurements of HIV-1 p24 antigen production as the
endpoint, requiring extensive washout of HIV-1-positive sera to avoid
artifacts but also reducing the sensitivity of the assay. While HIV-1
antibody neutralization in a single infectious cycle can be measured in
PBMC by using ﬂow-cytometry, this approach still involves several
complex handling steps (Darden et al., 2000; Mascola et al., 2002).
Thus, current PBMC-based assays are not easily amendable to high-
throughput and standardized analysis.
However, signiﬁcant improvements in assay standardization and
performance have been made by creating genetically engineered cell
lines as host-cell targets that stably express deﬁned levels of CD4, CCR5
and CXCR4 (Jones et al., 2007; Monteﬁori, 2005; Ochsenbauer-Jambor
et al., 2006; Platt et al., 1998; Richman et al., 2003;Wei et al., 2002). In
certain cell lines, reporter genes have been introduced that are
responsive toHIV-1 infection. For example, the TZM-bl cell line (Wei et
al., 2002) expresses ﬁreﬂy luciferase in response to Tat expression
following HIV-1 infection with either replication competent or Env-
pseudotyped viruses. TZM-bl cells enable sensitive, quantitative and
high-throughputmeasurements of HIV-1 infection and inhibitionwith
a linear dynamic range of several orders of magnitude (Monteﬁori,
2009; Wei et al., 2002), properties which contribute to their wide use
as an easily transferable and reproducible method for assessing
neutralizing antibody activity (Monteﬁori, 2009). Furthermore, it is
necessary to screen vaccine sera against panels of genetically diverse
viruses (Li et al., 2005; Li et al., 2006) to evaluate the breadth of
antibody responses elicited by vaccine immunogens, and for this
reason, pseudovirions have certain advantages. HIV-1 env genes can be
easily cloned from plasma viral RNA or infected cells, and coexpressed
by transfection with an env-minus viral backbone generating
infectious, replication-defective, Env-pseudotyped virus-like particles
(pseudovirions). In addition to the TZM-bl assay, another neutraliza-
tion assay utilizing pseudovirions is based on a viral backbone that, in
place of env, encodes the ﬁreﬂy luciferase gene which is expressed
subsequent to infection of target cells. This assay is robust in cell lines
(e.g. U87) that express CD4, CCR5 and CXCR4 (Binley et al., 2008;
Petropoulos et al., 2000; Richman et al., 2003). However, when PBMC
or other primary cells are used as targets of infection this pseudovirus
approach is not sufﬁciently robust due to a weak luciferase signal-to-
noise ratio, a limitation resulting in part from single-round infection
(Monteﬁori, unpublished). Furthermore, while these assays offer
certain advantages, pseudovirions which are produced in cell lines
like 293T do not always resemble virus produced in primary cells
(reviewed in (Ochsenbauer and Kappes, 2009)). Incorporation of
unprocessed gp160 (Herrera et al., 2005), producer-cell dependent
post-translationalmodiﬁcation of Envwith glycan (Willey et al., 1996)
and incorporation of host-cell proteins into progeny virions (Bastiani
et al., 1997; Fortin et al., 1997; Hioe et al., 2001; Rizzuto and Sodroski,
1997)may inﬂuence infectivity andneutralization sensitivity (Bastiani
et al., 1997; Sawyer et al., 1994;Willey et al., 1996; Zhang et al., 1997).
In this study,we describe an approach that combines the advantages
of PBMC-based assays with those of replication competent molecular
clones of reporter viruses. We introduce a recombinant HIV-1 proviral
backbone that preserves all viral open reading frames (orfs), is
replication competent, stably expresses Renilla reniformis luciferase
(LucR) and allows different env sequences to be shuttled in and
expressed in cis. This approach facilitates the construction of reference
panels encoding env sequences fromgenetically diverse strainsofHIV-1,including recently described transmitted/founder viruses (Keele et al.,
2008; Salazar-Gonzalez et al., 2008, 2009). The response of the LucR
readout to NAb is nearly identical to that of ﬁreﬂy luciferase when
measured in the TZM-bl assay. Using PBMCashost-cell targets, the Env–
IMC–LucR viruses enable sensitive, quantiﬁable assessment of infection
and NAb activity, which can be measured either within a single cycle or
after multiple rounds of virus replication. The robust and simpliﬁed
assay read out enables analysis of large sample numbers and, thus, the
approach represents a signiﬁcant advancement towards the establish-
ment of standardized high-throughput PBMC-based neutralization
assays.Results
Generation of a replication competent Renilla luciferase-expressing HIV-1
proviral DNA backbone
Since our objective was to create a versatile approach for sensitive
and quantitative analysis of HIV-1 infection and the inhibition thereof
in primary cells, we constructed a reporter HIV-1 proviral DNA
backbone, pNL–LucR.T2A, which is replication competent, encodes all
viral open reading frames and stably expresses a luciferase reporter
gene over multiple rounds of virus replication. The sea pansy Renilla
reniformis luciferase (LucR) gene was selected as a reporter since it
comprises fewer nucleotides (935 vs. 1652 with ﬁreﬂy luciferase), a
feature that we hypothesized would favor its retention within the
genome during virus replication. LucR was inserted into the genome
at the position of nef and linked in-frame at the 5′ end of nef with a
“self-cleaving” T2A sequence (54 nucleotides) (Fig. 1) (Szymczak et
al., 2004). During translation, the T2A sequence causes a ribosomal
skip that impairs normal amino acid peptide bond formation between
the penultimate glycine and the C-terminal proline (Fig. 1) (Donnelly
et al., 2001a,b). The ribosomal skip releases the newly synthesized
polypeptide as translation of the downstream sequence continues.
The principal purpose for constructing the pNL–LucR.T2A report-
er proviral DNA backbone was to facilitate the analysis of HIV-1
inhibitory molecules, particularly neutralizing antibodies, against
panels of env containing reference viruses in primary cells. Therefore,
a molecular strategy was devised to best accommodate the
expression of genetically diverse Envs within the pNL–LucR.T2A
3T.G. Edmonds et al. / Virology 408 (2010) 1–13backbone, generating the NL–LucR.T2A–Env.ecto constructs. All
LucR.T2A-containing proviruses described here are collectively
referred to as Env–IMC–LucR viruses (IMC – infectious molecular
clone) (Fig. 1 and Supplemental Fig. 1). The nucleotide sequence of
HIV-1 env comprises the Rev responsive element (RRE) as a product
of transcription, encodes the gp41 Env that interacts with p17Gag
(MA) via its cytoplasmic domain, and overlaps with the accessory
genes vpu, tat and rev. We elected to insert only the fragment of the
heterologous env that encodes the respective Env ectodomain
(Fig. 1), maintaining the NL4-3 cytoplasmic tail. This strategy retains
expression of all viral open reading frames (orfs), avoids genetic
chimerisms in tat and rev, and heterologous viral protein–protein
interaction between the gp41 tail and MA (Freed and Martin, 1995).
Further rationale for this strategy includes ﬁndings that show
(i) genetic recombination within the env membrane-spanning
domain (MSD) is one of few functionally favored env recombinant
points naturally occurring in vivo (Simon-Loriere et al., 2009) and
(ii) neutralization proﬁles of viruses bearing interclade recombinant
envs are predictable based on the clade/strain of the Env ectodomain
(Binley et al., 2004).
Three Env–IMC–LucR viruses (NL–LucR.T2A, NL–LucR.T2A–BaL.ecto
and NL–LucR.T2A–SF162.ecto) were analyzed by western blot in
comparison to the cognate viruses lacking the LucR.T2A insert (NL4-3,
NL–BaL.ecto, NL–SF162.ecto). Additional controls including NL–LucR–
T2A.FS and NLENG1–IRES were analyzed in parallel. NL–LucR–T2A.FS
has a frameshift (FS)mutation in the T2A sequence, impairing synthesis
ofNef. NLENG1–IRES (Kutsch et al., 2002; Levyet al., 2004)was included
as a Nef over-expressing positive control. Viral protein expression was
analyzed following the transfection of proviral DNA into 293T cells. Each
of the Env–IMC–LucR constructs expressed Nef at a similar or slightly
reduced level compared to the non-LucR.T2A parental viruses (Fig. 2A).
As expected, Nef expressionwas not detected from theNL–LucR–T2A.FS
virus. A replica blot probed with anti-Renilla luciferase antibody
indicated expression of LucR from the LucR.T2A-containing viruses
(Fig. 2B). Neither the anti-Nef nor the anti-LucR antibody detected a
band consistent with the molecular mass calculated for that of a LucR–
Nef fusion protein (data not shown), indicating the T2A peptide
functions efﬁciently to generate separated LucR and Nef proteins.
Probing with anti-GagMAb demonstrated the proteolytic processing of
Gagwasnormal (Fig. 2C) and that a similar amount of eachof theviruses
was produced and analyzed, results that were conﬁrmed by p24 ELISA
(data not shown).p55 / MA
p24 / CA
p36 / LucR
A
B
C
1     2     3    4     5    6     7    8     9
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Fig. 2. Viral gene expression in provirally transfected 293T. Western blot analysis of cell
lysates prepared from293T cells transfectedwith (1) NL4-3, (2)NL–LucR.T2A, (3) NL–BaL.
ecto, (4) NL–LucR.T2A–BaL.ecto, (5) NL–SF162.ecto, (6) NL–LucR.T2A–SF162.ecto, (7) the
nef frameshift negative control NL–LucR.T2A.FS, (8) mock-transfected cells and
(9) NLENG1–IRES. (A) HIV-1 Nef antiserum, (B) anti-Renilla and (C) anti-Gag MAbs
were used for detection.The infectivity of the reporter viruses was compared to that of the
cognate non-reporter viruses using the TZM-bl assay. In at least three
independent experiments, the titers of transfection-derived stocks
were found to be similar and ranged from 5×106 to 1×107 TZM-bl IU
per ml (data not shown). Infectivity per ng p24 was also comparable
for all of the virus stocks analyzed (data not shown). The linear range
of the LucR readout was examined by infecting TZM-bl cells in
triplicate at multiplicities of infection (MOI) equivalent to 10, 1, 0.1
and 0.01 (based on ß-galactosidase enumeration). After 48 h, the cells
were analyzed for both ﬁreﬂy luciferase (expressed by the TZM-bl cell
line) and LucR expression (from the integrated reporter provirus). A
linear response of both LucR and ﬁreﬂy luciferase activity was
detected for each virus at MOIs equal to 0.01, 0.1 and 1 (Fig. 3).
Moreover, infection with each of the Env–IMC–LucR viruses resulted
in nearly identical ﬁreﬂy luciferase values as their respective parental
non-reporter viruses, indicating similar infectivity in the TZM-bl cell
line. We further examined the effect of MOI on the linearity of the
LucR readout by calculating the ratio of virus-encoded LucR to TZM-bl
cell-encoded ﬁreﬂy luciferase at each virus inoculum (Table 1). The
ratios were similar at MOIs of 0.01, 0.1 and 1, consistent with the
linearity of LucR and ﬁreﬂy luciferase activity depicted in Fig. 3.
However, the ratio markedly increased at a MOI of 10, indicating
greater expression of LucR relative to that of ﬁreﬂy.
Additional genes inserted into the viral genome can have deleterious
effects on viral replication, i.e. severely delayed replication kinetics, andFig. 3. Comparison of cell-encoded ﬁreﬂy luciferase and virally-encoded Renilla luciferase
activity after infection of TZM-bl cells. TZM-bl cells were infected in triplicate with NL4-3,
NL–LucR.T2A, NL–BaL.ecto, NL–LucR.T2A–BaL.ecto, NL–SF162.ecto and NL–LucR.
T2A–SF162.ecto at a range ofMOIs. Two days post infection the cell lysates were analyzed
for (A) ﬁreﬂy luciferase expression and (B) LucR expression. All values are background
corrected (160 RLU for ﬁreﬂy luciferase; 180 for LucR). Error bars represent the standard
deviation.
Table 1
Ratio of Renilla to ﬁreﬂy luciferase.
Virus Multiplicity of infection
10.0 1.0 0.1 0.01
NL–LucR.T2A 2.5a 1.4 1.3 1.3
NL–LucR.T2A–BaL.ecto 8.2 1.1 1.0 0.9
NL–LucR.T2A–SF162.ecto 6.4 0.9 0.9 0.9
a The ratio was determined in TZM-bl cells 2 days after infection with the indicated
viruses.
4 T.G. Edmonds et al. / Virology 408 (2010) 1–13deletions can be rapidly selected. To determine whether the Env–IMC–
LucR reporter viruses were replication competent, 2×106 PHA-P
stimulated PBMC were infected at a low MOI of 0.0025 (equivalent to
5×103 TZM-bl IU) with NL–LucR.T2A, NL–LucR.T2A–BaL.ecto, NL–LucR.
T2A–SF162.ecto, and the respective non-LucR.T2A parental viruses.
Representative results from independent experiments, measuring p24
antigen production as an endpoint, demonstrate that the Env–IMC–LucR
viruses are replication competent and have only slightly delayed
replication kinetics compared to their respective non-reporter parental
viruses (Fig. 4). Similar results were obtained when PBMC from
additional donors were used (data not shown). Smaller differences in0 5 10 15
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Fig. 4. Renilla luciferase encoding HIV-1 reporter viruses are replication competent in
PHA-P stimulated PBMC. Replication kinetics of the Env–IMC–LucR viruses (A) NL–LucR.
T2A–SF162.ecto, (B) NL–LucR.T2A and (A, B) NL–LucR.T2A–BaL.ecto were compared to
those of the respective non-reporter parental viruses NL4-3, NL–BaL.ecto andNL–SF162.
ecto. PHA-P stimulated PBMC were infected overnight (MOI of 0.0025), washed twice
and cultured for 14 days in 5 mL of medium. 2 mL supernatants were collected at the
indicated time points to measure p24 antigen and the medium removed from the
sampleswas replenished. (A) On day 6, the cell cultureswere split 1:2 and fedwith fresh
medium and uninfected cells from the same donor. (B) On day 6, the cell cultures were
split 1:2 and fed with fresh medium only. Data in A and B represent results from two
independent experiments with PBMC from different donors.replication kinetics were observedwhen PBMCwere infected at a higher
MOI (data not shown).
Next, we examined whether the LucR gene was stably maintained
in, and expressed from, the viral genome over multiple cycles of virus
replication. For this, PHA-P stimulated PBMC were infected with
transfection-derived NL–LucR.T2A–BaL.ecto and NL–LucR.T2A–SF162.
ecto viruses (5×103 IU=MOI of 0.0025). Culture supernatants
containing virus were collected after 6, 9 and 14 days and cryopre-
served. TZM-bl cells were then infected in triplicate with 3 ﬁve-fold
dilutions of the 293T transfection- and PBMC infection-derived virus
supernatants. Overall infectivity was measured by cell-encoded ﬁreﬂy
luciferase activity while LucR activity was determined to assess the
relative viral reporter gene expression. Values from those input
dilutions yielding relative light unit (RLU) values within the linear
range (as determined in Fig. 3) were then used to calculate the ratios
of LucR to ﬁreﬂy luciferase. As shown in Fig. 5, the ratios remained
essentially constant, indicating that per infectious unit of virus
produced in PBMC over time, expression of virally-encoded LucR did
not change signiﬁcantly. These results were reproduced in three
separate experiments and the ﬁndings indicate that LucR is stable
within the reporter virus backbone over multiple rounds of
replication. In an additional experiment (data not shown), infected
PBMC cultures were either carried over 28 days by feeding with
freshly stimulated cells every ﬁve days or 500 μl volumes of PBMC
supernatants were passaged cell-free onto fresh PBMC every sevenFig. 5. The Renilla luciferase gene expression from the HIV-1 genome remains stable
after multiple rounds of replication in PHA-P stimulated PBMC. 293 T transfection-
derived (TD) viruses, (A) NL–LucR.T2A–BaL.ecto and (B) NL–LucR.T2A–SF162.ecto,
were allowed to replicate in PBMC for 14 days and culture supernatants collected on
days 6, 9 and 14 after infection. The TD virus stock and the cell-free PBMC supernatants
from each sample day were cryostored until used to infect TZM-bl cells in replicates.
TZM-bl lysates were analyzed for expression of both luciferase reporters and the ratio of
virally-encoded LucR to cell-encoded ﬁreﬂy luciferase (as a measure of overall
infectivity) was determined for each time point. Error bars represent the standard
deviation.
5T.G. Edmonds et al. / Virology 408 (2010) 1–13days. Virus supernatants harvested on the days of feeding were
analyzed as described for Fig. 5. Under these conditions, a reduction in
LucR expression was observed, indicating that LucR expression will
decrease after an extended time in culture (data not shown).
Analysis of HIV-1 neutralizing antibodies in TZM-bl and NOMI cells
The infection of TZM-bl cells, as quantiﬁed by LucR expression,
closely correlated with quantiﬁcation via ﬁreﬂy luciferase. This
supported the notion that the NL–LucR.T2A reporter virus backbone,
and the LucR readout, would enable sensitive measurement of
neutralizing antibody activity against HIV-1. Therefore, a systematic
analysis was undertaken by analyzing neutralization in two different
cell lines, as well as PBMC, with Env–IMC–LucR reporter viruses
expressing HIV-1 envs from different virus strains, including transmit-
ted/founder viruses. First, the NL–LucR.T2A–BaL.ecto and NL–LucR.
T2A–SF162.ecto reporter viruses were analyzed in the cell lines, TZM-bl
and NOMI. The viruses were incubated for 1 h with dilutions of each of
three broadly neutralizing antibodies (NAbs) (IgG1b12, 2G12 and4E10)
or the T20 fusion inhibitor. Thereafter, the virus/inhibitor mixture was
added to either the TZM-bl or NOMI cells and inhibition was assessed
two days later by measuring virus-encoded LucR activity in the cell
lysates (Fig. 6). The TZM-bl cell lysates were also assessed for cell-
encodedﬁreﬂy luciferase activity. As expected, in TZM-bl cells theﬁreﬂy
luciferase readout showed therewas a dosage dependent effect for each
inhibitor on virus infectivity. For both viruses tested, the “% neutrali-
zation” curves for the LucR readoutwere nearly identical to those of the
ﬁreﬂy readout (representative results shown in Figs. 6A and B). IC50
values were calculated from multiple independent experiments (n=3
to 4) using both the LucR and the ﬁreﬂy luciferase readout. As shown in
Figs. 6C and D, the LucRmeasurements (illustrated with solid symbols)
were highly reproducible, and similar to those generated when
measuring TZM-bl ﬁreﬂy luciferase (shown with open symbols).
When neutralization was analyzed using NOMI cells (reporter T-cellsT20
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Fig. 6. Neutralization assay in TZM-bl and NOMI cells utilizing Renilla luciferase-expressing vir
dilutions of the T20 fusion inhibitor and theNAbs IgG1b12, 2G12 and 4E10 for 1 h prior to infect
presenceofDEAE-Dextran (40 μg/mL) orNOMI cells (MOIof 0.15) and incubated for 48 h.After
expression and the NOMI cells were analyzed for LucR expression. (A and B) TZM-bl data were
represent the FF (open symbols) and LucR (solid symbols) IC50 values obtained from 3 to 4 ind
The LucR and FF IC50 values for each experiment are depictedwith corresponding shapes. The Lu
(F) NL–LucR.T2A–SF162.ecto are also depicted. Error bars represent the standard deviation.grown in suspension) as targets of infection, very similar dose–response
curves were generated in independent experiments (data not shown).
Additionally, the level of inter-assay variation was relatively small. In 5
to 6 independent experiments with NL–LucR.T2A–BaL.ecto, the mean
IC50 values for T20, IgG1b12, 2G12 and 4E10 were 0.15±0.03, 0.47±
0.25, 1.17±1.2 and 8.74±4.71, respectively (Fig. 6E). Utilizing NL–
LucR.T2A–SF162.ecto, the mean IC50 values in 5 independent experi-
ments for T20, IgG1b12, 2G12 and 4E10 were 0.78±0.09, 0.24±0.14,
2.56±1.59 and 13.33±6.26, respectively (Fig. 6F).
Analysis of HIV-1 antibody inhibition in primary PBMCwith the NL–LucR.
T2A–Env.ecto reporter backbone
While recombinant reporter cell line based assays are widely used to
analyze NAb activity, these assays do not always give the same results as
those generated using PBMC (Binley et al., 2004; Brown et al., 2007;
Moody et al., 2010), highlighting the importance of using primary cells,
including PBMC, to screen NAbs and/or patient plasma for anti-viral
activity. To examine the utility of the Env–IMC–LucR reporter viruses in a
PBMC-based assay, we analyzed neutralization of the NL–LucR.T2A–BaL.
ectoandNL–LucR.T2A–SF162.ecto virusesbymeasuringRenilla luciferase
two days after infection. Normal human PHA-P stimulated PBMC were
infected in 96-well plates at an MOI of 0.625 in the presence of IgG1b12,
2G12, 4E10 or T20. Two days post infection, there was a clear dose–
response inhibitory effect for each inhibitor tested (Figs. 7A and B),
demonstrating utility of the Env–IMC–LucR reporter backbones for
analyzing NAb activity.
The two-day assay is of sufﬁcient duration that the virus likely
replicates beyonda single cycle of infection, resulting inRLUvaluesup to
four logs above the negative control for the viruses andMOI tested here.
Next, we determined whether the assay sensitivity was sufﬁcient to
quantify a single cycle of virus infection and, ultimately, NAb inhibition
thereof. PBMCwere infectedwithNL–LucR.T2A–SF162.ecto (MOI=0.2)
in medium supplemented with or without 2 μM of the proteaseb12 2G12 4E10
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6 T.G. Edmonds et al. / Virology 408 (2010) 1–13inhibitor Indinavir (IDV), a concentration sufﬁcient to inhibit nearly all
secondary infection. In IDV treated cultures, LucR RLU values began to
plateau at approximately 40 h post infection, reaching approximately
15,000 RLU above the uninfected control. In the non-treated culture
clear evidence of secondary infectionwasﬁrst detected at 48 h (Fig. 7C).
While recognizing that differences exist among viruses with respect to
infectivity, this result demonstrates feasibility for analyzingNAbactivity
in PBMC against cell-free virus infection in a single cycle assay format.
On the other hand, because Env–IMC–LucR viruses are replication
competent and stably expresses LucR, the assay timemay be extended,thereby increasing the luciferase signal-to-noise ratio, particularly at
lower virus inoculums. Allowing multiple rounds of virus replication
wouldmore closelymimic the classic PBMC neutralization assay, which
measures p24Gag as an endpoint several days post infection. Therefore,
we demonstrated feasibility of this approach by analyzing inhibition of
virus (NL–LucR.T2A–SF162.ecto) four days after infection against a
reference panel of inhibitors commonly used in the conventional PBMC
assay. Each inhibitor analyzed, includingMAbs, sCD4, HIVIG and pooled
clade-speciﬁc plasma, exerted an inhibitory dosage–response effect
(Figs. 8A and B).
To further validate the assay platform, we expanded the analysis to
include a broader panel of envs expressed in the pNL–LucR.T2A
reporter backbone, including the transmitted/founder (T/F) clade B
viral envsWITO4160, WEAU0575, CH040, CH058 and CH077 (Keele et
al., 2008). The infectivity and replication competence of each
recombinant virus was demonstrated in the TZM-bl assay and in
PBMC, respectively, to be similar to the cognate parental virus (data
not shown). Furthermore, experiments to be reported elsewhere
demonstrated that the cellular tropism of these recombinant viruses
was identical to that observed for the parental full-length T/F viruses
(Ochsenbauer et al., unpublished). Using PBMC from a single donor,
inhibition of ﬁve T/F env-reporter viruses and two control env-
reporter viruses (NL–LucR.T2A–BaL.ecto and NL–LucR.T2A–SF162.
ecto) was analyzed against NAbs, sCD4, HIVIG and clade-speciﬁc
pooled plasma. The inhibitory activity of each inhibitor is illustrated as
IC50 and IC80 values (Table 2). The results indicate that (i) the assay (in
PBMC) measured an IC50 and in most cases an IC80 for BaL and SF162
(Tier 1 viruses) against sCD4, HIVIG and MAbs, (ii) with just a few
Table 2
Analysis of HIV-1 inhibition by clade-speciﬁc pooled plasma from HIV-1 infected subjects, HIVIG, sCD4 and MAbs.
Inhibitors BaL SF162 WITO4160 WEAU0575 CH040 CH058 CH077
IC50a IC80 IC50 IC80 IC50 IC80 IC50 IC80 IC50 IC80 IC50 IC80 IC50 IC80
Concentration (μg/mL) sCD4 1.3 1.7 4.1 8.9 N25 N25 12.3 27.7 7.6 31.7 41.5 N25 2.8 13.9
IgG1b12 3.5 6.4 1.7 4.7 N25 N25 6.5 24.5 1.6 24 24.1 N25 1 3.4
2G12 0.23 0.7 0.08 0.2 0.05 0.2 0.02 0.1 N25 N25 b0.02 0.04 b0.02 0.5
2F5 39 N25 23.5 37.4 25.2 39.9 6.7 12.7 1.7 11.3 2.7 8.8 1.8 12.4
4E10 11.4 17.3 9.7 15.6 7.6 14.5 8.9 21.4 2 6.5 4.5 21.2 0.6 10
HIVIG 789 1610 184 465 2160 N2500 1739 N2500 310 753 1241 2325 4.1 428
Plasma dilution 1648 b20 b20 107 35 b20 b20 b20 b20 145 b20 b20 b20 338 b20
1652 b20 b20 44 b20 35 b20 b20 b20 11,829 36 209 b20 15,315 233
1686 355 161 540 46 b20 b20 b20 b20 1180 33 261 36 697 58
BB81 7976 92 10,896 213 2979 63 901 66 61 b20 24 b20 886 123
BB87 14,119 565 N43,740 873 129 b20 4968 266 N/A N/A N/A N/A N/A N/A
a IC50 and IC80 values determined using NL–LucR.T2A.Env.ecto viruses to infect PBMC from one donor. Values were calculated by measuring Renilla luciferase four days after
infection.
7T.G. Edmonds et al. / Virology 408 (2010) 1–13exceptions, the T/F viruses exhibited similar sensitivity toMAbs as the
Tier 1 controls, (iii) T/F viruses were generally most sensitive to the
2G12, 2F5, and 4E10 MAbs, (iv) T/F viruses were generally less
sensitive to sCD4 compared to control viruses, and (v) with few
exceptions, T/F viruses are similarly resistant (b20) to plasmas 1648
and1652 andmore resistant to plasmas 1686 andBB81 comparedwith
NL–LucR.T2A–BaL.ecto and NL–LucR.T2A–SF162.ecto.
Differences in the susceptibility of different donor PBMC to virus
infection have been reported (Spira and Ho, 1995), and anecdotal
evidence also suggests donor dependent variation of neutralization
sensitivity. Facilitated by the high-throughput capability of this
approach, the observation of variation in neutralization activity0.01
0.1
1
10
100
IC
50
 (μ
g/
m
L)
HIVIG
0.1
1
10
100
1000
10000
Donor  PBMC
IC
50
 (μ
g/
m
L)
A IgG1b12
Donor PBMC
B
C D
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expression. Each bar represents an individual donor PBMC (same order A through D). (A) IgG
inhibited in 57 of 75 (76%) of PBMC with a mean IC50 of 9.5±6.5 μg/mL. (C) HIVIG inhibited
from the 75 donors were also infected with NL–LucR.T2A–BaL.ecto without the presence ofamong different donor PBMC was analyzed. In 75 different donor
PBMC, we quantiﬁed susceptibility to infection by NL–LucR.T2A–BaL.
ecto, and virus inhibition by IgG1b12, 4E10 and HIVIG (Fig. 9). For the
75 different donors analyzed, the mean LucR value in the absence
of inhibitor was relatively uniform, with a mean of 36,530±18,525
LucR RLU (Fig. 9D) and a range of approximately 20-fold. Using IC50 as
a cutoff, IgG1b12, 4E10 and HIVIG were inhibitory in 100%, 76%
and 100% of the donor PBMC, with mean IC50 values of 3.9±4.2 μg/mL,
9.5±6.5 μg/mL and 300.9±369.4 μg/mL, respectively (Figs. 9A–C).
Using IC80 as the cutoff, IgG1b12, 4E10 and HIVIG were inhibitory
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among the different donor PBMC. IgG1b12 IC50 values ranged from 0.06
to 24.01 μg/mL (400-fold), 4E10 from 0.08 to N25 μg/mL (N300-fold)
and HIVIG from 0.5 to 2050 μg/mL (4100-fold). Similar results were
obtained in repeat neutralization assays with PBMC from a subset of 12
donors, indicating that the high variability was a real biologic effect and
not simply assay-to-assay variability. Interestingly, for a given donor
PBMC a consistent pattern of variation was not observed among the
three inhibitors tested. For example, potent inhibition by IgG1b12 for a
given donor PBMC did not necessarily correlate with strong virus
inhibition by the other antibodies in the same donor PBMC. A possible
explanation for the observed variation could be the differences in the
susceptibility of different donor PBMC to virus infection. However,
although differences in virus susceptibility were observed, the range
was much smaller (approximately 20-fold) than for variation of
neutralization, and there was not an apparent correlation with
neutralization sensitivity.
To further address this point, we analyzed inter-assay variation
using two different donor PBMC in three independent experiments
each. The two donors PBMC were infected with NL–LucR.T2A–BaL.
ecto in the presence of 4E10, 2F5, IgG1b12, 2G12 and sCD4,
respectively (Fig. 10). The range in IC50 values for each inhibitor
was relatively small for each PBMC donor. For Donor 1, 4E10 IC50
values ranged from 0.02 to 0.09 μg/mL, 2F5 from 0.53 to 1.25 μg/mL,
IgG1b12 from 0.2 to 0.36 μg/mL, 2G12 from 0.008 to 0.32 μg/mL and
sCD4 from 1.01 to 2.03 μg/mL. For Donor 2, 4E10 IC50 values ranged
from 0.22 to 0.39 μg/mL, 2F5 from 0.50 to 0.56 μg/mL, IgG1b12 from
0.09 to 0.35 μg/mL, 2G12 from 0.03 to 0.56 μg/mL and sCD4 from 0.59
to 0.61 μg/mL. This result would argue that themagnitude of variation
in IC50 values observed among the 75 PBMC donors was not due to
inherent variability in the NL–LucR assay platform itself, but was in
fact a characteristic of the primary cells. A comprehensive study of this
phenomenon will be reported elsewhere by Wieczorek et al.Donor 1
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Fig. 10. Analysis of inter-assay variation in two donor PBMC. NL–LucR.T2A–BaL.ecto
was preincubated with dilutions of 4E10, 2F5, IgG1b12, 2G12 and sCD4 for 1 h prior to
infection. The inhibitor/virus mixture was then placed on PBMC from two different
donors and four days post infection the cells were lysed and analyzed for LucR
expression. For each donor, the IC50 values depicted are for 3 independent experiments.Discussion
The assessment of immunization strategies for eliciting potent and
broadly neutralizing antibodies requires standardized, high-through-
put, transferable in vitro assays informative of NAb potency and breadth
in vivo. Signiﬁcant progress in assay standardization has been made
through technologic advances in genetically engineered cell lines and
pseudovirion-based assays (2005; Li et al., 2005, 2006; Mascola et al.,
2005a; Monteﬁori, 2009; Richman et al., 2003). In 2005, the Laboratory
Standardization Subcommittee for the Global HIV/AIDS Vaccine
Enterprise (GHAVE) recommended these methods as a standardized
approach to assess sera NAbs from vaccine trials (2005; Mascola et al.,
2005a; Monteﬁori, 2009). However, qualitative and quantitative
differences in NAb-virus inhibition have been identiﬁed between this
assayplatformandprimary cell-basedNAb assays (reviewed in (Polonis
et al., 2009)). For example, MAb to phosphatidylinositol phosphate is
inhibitory to HIV-1 infection when analyzed in the PBMC assay but not
in the TZM-bl assay (Brown et al., 2007). In a collaborative study with
Moody and colleagues, we recently validated these ﬁndings and
elucidated a mechanism for these differences utilizing the Env–IMC–
LucR viruses described here (Moody et al., 2010). Discrepancies have
also been reported for the MAbs 4E10 and X5 when analyzed in PBMC
assays compared with pseudovirion assays. For example, 4E10
neutralized all tested viruses in the pseudovirion assay but not in the
PBMC assay (Binley et al., 2004) whereas the X5 MAb neutralized virus
in the PBMC assay but not in the pseudovirus assay. These ﬁndings
highlight the importance of using primary cells, including PBMC, to
screen NAbs and/or patient plasma for anti-viral activity. Moreover,
since correlates between in vitro assay measurements of neutralizing
activity and in vivo protection are not known, assessment of NAbs using
different assay approaches is currently recommended (Fenyo et al.,
2009; Pantophlet and Burton, 2006; Polonis et al., 2008, 2009). Thus, the
concept behind this report, and the Env–IMC–LucR viruses, was
development of a virologic approach to overcome problems of the
PBMC-based assay that to date have limited its utility in the global
vaccine discovery effort. Key features of the Env–IMC–LucR-based assay
that underpin a signiﬁcant advancement in PBMC assay performance
and eventual integration into the armamentarium for vaccine trials
immunemonitoring include, (i) expression of env fromwithin the viral
genome (in cis), (ii) replication of the recombinant virus beyond a single
cycle of infection, (iii) a highly speciﬁc, sensitive and quantiﬁable
endpoint (LucR) amenable to high-throughput testing and standardi-
zation, (iv) stable expression of LucR in the viral genome over multiple
cycles of replication, (v) a molecular strategy for expressing functional
envs (including those from other viral clades) in the pNL–LucR.T2A
backbone with minimal disruption to other viral genes, and cis- and
trans-acting functions, and (vi) the versatility to assess NAbs in various
(primary) host-cell targets and assay formats.
In response to discordant results observed between recombinant/
pseudovirion- and PBMC-based assay platforms, the Comprehensive
Antibody Vaccine Immuno-Monitoring Consortium (CA-VIMC) has been
exploiting Env–IMC–LucR viruses to establish a standardized PBMCassay
for assessing vaccine sera. One of the principal challenges is inter-
laboratory and inter-assay variation. At least in part, this may be due to
the differential susceptibility of different donor PBMC to HIV-1 infection
(Spira and Ho, 1995) as well as detection of neutralization (Polonis et al.,
2009). Taking advantage of the high-throughput capability and accuracy
of the Env–IMC–LucR-based assay, we examined variation in measure-
ment of NAb potency among 75 different donor PBMC. Using a single
stock of virus (NL–LucR.T2A–BaL.ecto) to infect thePBMC in the presence
of HIVIG and the MAbs IgG1b12 and 4E10, we demonstrated a level of
donor-to-donor variability that exceeded 2 orders of magnitude in IC50
values (Fig. 9). Similar variation among the same 75 donor PBMC was
observed with the anti-phospholipid MAb PGN632, reported elsewhere
(Moody et al., 2010). The 75 donor PBMC were also analyzed for
susceptibility to NL–LucR.T2A–BaL.ecto infection, and while differences
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inhibition (Fig. 9D). Importantly, our data indicate that inter-assay
variation does not per se result from the reporter virus-based assay
platform, but that high variabilitywas a real biologic effect attributable to
use of different donor PBMC. When independent experiments were
repeated multiple times on PBMC from two individual donors,
respectively (Fig. 10), the ranges in IC50 values for each inhibitor were
low for each respective donor PBMC. Moreover, using a similar assay
conﬁguration to assess neutralization in the NOMI T-lymphocyte cell
line (Jones et al., 2007), minimal inter-assay variation was observed:
IgG1b12 and 4E10 demonstrated a 4.98-fold and 4.16-fold variation in
IC50 values, respectively (Figs. 6E and F). Thus, our ﬁndings demonstrate
substantial differences in the extent of antibody neutralizationmeasured
among different donor PBMC. Studies to elucidate factors that account
for differences in NAb potency detected among different donor PBMC,
and to overcome the resulting assay limitations, are ongoing within the
CA-VIMCandwill be reportedelsewhere (Wieczoreket al., unpublished).
It has been recommended that the magnitude and breadth of NAb
responses elicited by vaccine immunogens be assessed against panels of
genetically diverse viruses (Mascola et al., 2005a). For the pseudovirion
assay, such panels of reference envs have been generated as molecular
clones that are cotransfected with an HIV-1 env-deﬁcient provirus to
generate deﬁned stocks of pseudotyped VLPs (Li et al., 2005, 2006;
Seaman et al., 2010).While the pseudovirion platform is very conducive
to the analysis of large panels of envs, it has certain limitations (Polonis
et al., 2009). Therefore, the Env–IMC–LucR concept incorporated a
molecular strategy enabling panels of different env (heterologous
ectodomain-encoding region) expressing viruses to be generated,
including those from recently described transmitted/founder viruses
(Keele et al., 2008), since it is this virus that antibody must inhibit to
prevent transmission. Several molecular genetic and virologic con-
siderations guided our approach for cloning and expressing env genes of
other viral strains, including those from other clades, in the pNL–LucR.
T2A backbone. First, the HIV-1 env orf overlaps with vpu and the second
exons of both tat and rev. Second, Env incorporation into virions during
assembly is facilitated by interaction of amino acids in the C-terminus of
Env with those in the N-terminus of p55Gag (Freed and Martin, 1995).
Since insertion of the entire heterologous env gene into the pNL–LucR.
T2A backbone would create genetic chimerisms with tat, rev and vpu,
and heterologous protein–protein (MA–Env) interaction, our strategy
comprised only the part of the heterologous Env that is exposed on the
surface of the virus (the ectodomain) while maintaining the NL4-3 Env
cytoplasmic tail. However, the mRNA from which Env is translated
forms a complex secondary structural motif (the Rev responsive
element, RRE) that mediates the export of unspliced and singly spliced
viral RNA from the nucleus via interaction with Rev (Daly et al., 1989),
and thus, our molecular strategy of expressing only the ectodomain of
the heterologous env does create a heterologous Rev–RRE interaction
(but avoids a chimeric Rev protein). Additional rationale supporting the
ectodomain approach was based on observations that neutralization
phenotypes of naturally occurring interclade viral recombinants, with
recombination points within the env membrane-spanning domain
(MSD), were predictable based on the clade/strain of the Env
ectodomain (Binley et al., 2004); and genetic recombination within
theMSD, which is highly conserved, is one of few functionally preferred
env recombinantpoints that naturally occur in vivo (Simon-Loriere et al.,
2009). A panel comprising 27 different clade B envs (ectodomain) has
been constructed in the pNL–LucR.T2A backbone to date (Ochsenbauer
and Kappes, 2009), all of which are infectious in PBMC. Panels
comprising clade C and A/E envs are currently being constructed and
characterized (with 5 and 11 envs, respectively).
Recombinant HIV-1 genomes engineered to express luciferase
have been previously described (Chen et al., 1994; Connor et al.,
1995; Garcia-Perez et al., 2007; Mariani et al., 2000; Pohlmann et al.,
2001; Tokunaga et al., 2001). However, many of these approaches
delete either all or part of the viral env or nef genes in order to insertthe luciferase gene. While some of these recombinants may produce
infectious virus that report via expression of luciferase from
integrated proviral DNA, recombinant virus conﬁgurations compris-
ing gene deletions can have deleterious consequences on important
virologic function and limit utility of the reporter viruses. Since our
goal was to create a luciferase reporter virus that resembled wild-
type virus as closely as possible, the Env–IMC–LucR viruses were
designed to be replication competent and express all viral genes. Our
strategy for retaining efﬁcient expression of nefwas to position LucR
and nef on the same spliced mRNA linked in-frame via T2A (LucR/
T2A/nef). The LucR gene was selected over ﬁreﬂy luciferase to
minimize extending the length of the viral genome. Similarly, the T2A
sequence is also much shorter than alternative approaches like IRES.
This may, at least in part, explain the relative stability of the
recombinant Env–IMC–LucR viruses, which to our knowledge is an
important feature that distinguishes this construct from those
previously reported. One potential limitation of the T2A approach
is that the ribosomal skip mechanism of T2A occurs between the
penultimate Gly and adjacent Pro, thus the Nef protein does not have
an authentic N-terminus. Consequently, it is unlikely that Nef is post
translationally modiﬁed by myristoylation, which is important for
Nef to associate with the cell's cytoplasmic membrane (Kaminchik et
al., 1991) and function in the internalization of various cellular
membrane proteins including CD4 andMHC-I (reviewed in (Piguet et
al., 1999)). However, work by Bentham et al. suggests that N-
terminally mutated, non-myristoylated Nef may partially retain
membrane association and low levels of CD4 down regulation
(Bentham et al., 2006). Thus, additional studies of the Env–IMC–
LucR viruses will be required to understand how the altered N-
terminus affects Nef function. Nevertheless, our results clearly
indicate that the Env–IMC–LucR viruses express the Nef protein
and replicate in PBMC with kinetics similar to wild-type virus.
Furthermore, due to the presence of Nef, the Env–IMC–LucR viruses
have proven useful in CTL assays (Freel et al., 2010), including those
in which responses might be directed against Nef epitopes.
In summary, our ﬁndings demonstrate a signiﬁcant advancement
toward the establishment of a standardized PBMC-based neutralization
assay platform capable of assessing the quality and potency of NAbs
elicited by HIV-1 vaccine immunogens in clinical trials. Although the
work described here is focused solely on neutralization in PBMC, the
approach was designed to allow for virus infection and/or inhibition
assays in any desired target cell, including primary monocyte-derived
macrophages, or cells comprisingmucosal tissue. Results highlighting the
utility of this approach in other primary cell types will be reported
elsewhere. The advancements described here are being explored to
potentially elucidate immunological correlates of protection against HIV-
1 infection recently reported for the ALVAC-HIV and AIDSVAX B/E
vaccine regimen that was administered in a Thailand community-based
populationwith largely heterosexual risk (Rerks-Ngarmet al., 2009). The
Env–IMC–LucR-based viruses described here represent new virologic
tools that will facilitate the routine application of a standardized PBMC
neutralization assay in the assessment of sera from HIV vaccine trials.
Materials and methods
Cells
The TZM-bl cell line (Wei et al., 2002) was obtained from the NIH
AIDS Research and Reference Reagent Program (NIH ARRRP), Division
of AIDS, NIAID,NIH (catalog no. 8129), contributed by JohnKappes and
Xiaoyun Wu. 293T cells were obtained from the American Type
Culture Collection (ATCC) (CRL-11268). Both cell lines were main-
tained in Dulbecco'smodiﬁed Eagle'smedium (DMEM) supplemented
with 10% heat inactivated fetal bovine serum (FBS), penicillin
(100 U/mL) and streptomycin (100 U/mL). NOMI cells (Jones et al.,
2007), a Jurkat-derived cell line engineered to constitutively express
10 T.G. Edmonds et al. / Virology 408 (2010) 1–13high levels of CD4 and CCR5, and express EGFP upon infectionwithHIV
(generously provided by Dr. Olaf Kutsch), were maintained in RPMI
1640 growth medium supplemented with penicillin (100 U/mL),
streptomycin (100 U/mL) and L-glutamine (2 mM).
Human primary peripheral blood mononuclear cells (PBMC) were
isolated by Ficoll gradient from buffy coats obtained from healthy
HIV-1 seronegative donors. Buffy coats were purchased from Research
Blood Components (Brighton, MA) or puriﬁed PBMC were provided
by Tom Denny (Duke University) and the CAVD CTC-VIMC, as funded
by the Bill & Melinda Gates Foundation (grant number 38650). PBMC
were cultured in RPMI 1640 growth medium supplemented with
penicillin (100 U/mL), streptomycin (100 U/mL), L-glutamine
(2 mM), interleukin-2 (IL-2) (30 U/mL) (Roche, Indianapolis, IN)
and 10% FBS. The cells were stimulated by culturing in growth
medium containing phytohemagglutinin (PHA)-P (2–5 μg/mL)
(Sigma-Aldrich) for 24 h. The next day, the medium was removed
and the cells were placed into culture with RPMI 1640 containing IL-2
(30 U/mL) and used either immediately, or within 4 days.
Antibodies and anti-viral drugs
Antibodies included HIV-1 Nef antiserum (NIH ARRRP, Catalog
#2949, contributed by Ronald Swanstrom), monoclonal antibody
(MAb) 183-H12-5C to HIV-1 capsid (NIH ARRRP, contributed by Bruce
Chesebro and Hardy Chen), MAb IgG1b12 to HIV-1 gp120 (generously
provided by Dennis Burton), MAb 2G12 to HIV-1 gp120 (NIH ARRRP,
contributed by Hermann Katinger), MAb 2F5 to HIV-1 gp41 (NIH
ARRRP, contributed by Hermann Katinger), MAb 4E10 to HIV-1 gp41
MPER (purchased from Polymun GmbH, Vienna, Austria), and HIVIG
(Human Immunodeﬁciency Virus Immune Globulin) (NIH ARRRP,
contributed by Luiz Barbosa), puriﬁed IgG prepared from pooled
plasma of asymptomatic HIV-1 antibody positive donors with CD4+
counts above 400 cells. The MAb to Renilla luciferase, clone 5B11.2,
was purchased from Chemicon International (Catalog no. MAB4400).
sCD4 was purchased from Progenics Pharmaceuticals, Inc., Tarrytown,
New York. Subtype B plasma samples (1648, 1652 and 1686) were
obtained by Duke University (D. Monteﬁori) from Zeptometrix
Corporation (Buffalo, NY). Subtype C plasma samples (BB81 and
BB87) were purchased from the South African National Blood Services
(Johannesburg) and provided by Lynn Morris, National Institute for
Communicable Diseases, Johannesburg, South Africa. The clade A pool
(E. Africa), clade C Pool (Tanzania), clade C Pool (Ethiopia) and clade B
Pool (United States) were provided by Victoria R. Polonis,Walter Reed
Army Institute of Research, Rockville, MD (Seaman et al., 2010). The
fusion inhibitor (T20) was obtained from Trimeris, Inc., Durham,
North Carolina. The HIV-1 protease inhibitor, Indinavir Sulfate (IDV),
was obtained from the NIH ARRRP, Division of AIDS, NIAID.
Proviral plasmid construction
To generate a luciferase-expressing, replication competent HIV-1
proviral DNA (designated pNL–LucR.T2A), the Renilla reniformis luciferase
reporter gene (LucR) fromthephRL–CMVvector (Promega) (GenBank ID:
AF362549), and a T2A peptide coding sequence (Szymczak et al., 2004)
were fused in-frame by PCR methods and inserted between the HIV-1
NL4-3 (GenBank ID: M19921) env and nef genes (Fig. 1; see also
Supplemental Fig. 1). A LucR/T2A/nef (partial) cloning cassette was ﬁrst
engineered by PCR for insertion into a speciﬁcally constructed shuttle
vector (pCB6_NL_env/nef). Brieﬂy, the LucR genewas ampliﬁed from the
phRL–CMV vector with the sense primer LucForward, 5′-TAAGCTAGCCA-
CCATGGCTTCCAAGGT-3′ (NheI restriction site is italicized and the LucR
start codon is underlined), and the antisenseprimer LucR/T2AReverse, 5′-
TCTAGATGGGCCAGGATTCTCCTCGACGTCACCGCATGTTAGCA-
GACTTCCTCTGCCCTCCTGCTCGTTCTTCAGCACGCG-3′ (XbaI restrictionsite
is italicized and the T2A peptide sequence is underlined). The reverse
primerwas designed to remove the stop codon from the LucR gene and tofuse the T2A peptide coding sequence in-frame at the 3′ end of the
luciferase gene. In addition, a 5′ fragment of the nef gene was ampliﬁed
from the NL4-3 genome using the sense primer T2A/nefFoward, 5′-
AATCCTGGCCCATCTAGAATGGGTGGCAAGTGGTCA-3′ (T2A sequence is
underlined, XbaI restriction site is italicized and the nef start codon is
bolded and underlined), and the antisense primer nefReverse, 5′-
AGGGAAGTAGCCTTGT-3′ (anneals at NL4-3 nt 10142–10157 down-
stream of the viral XhoI restriction site (NL4-3 nt 8887) in nef). The T2A/
nefForward primer was designed to be partially complementary to the
LucR/T2AReverse primer allowing the two puriﬁed PCR products to
anneal in a thirdPCRreactionusingprimers LucForwardandnefReverse to
generate a “fusion” PCR product. The fusion PCR product was then cloned
into the shuttle vector pCB6_NL_env/nef, a vector derived from plasmid
pCB6–EnvA (Ochsenbauer-Jambor et al., 2002) andmodiﬁed to contain a
fragment of the HIV-1 NL4-3 genome fromBamHI (NL4-3 nt 8465) in env
to KpnI (NL4-3 nt 9005) in nef, utilizing the restriction sites NheI (a
speciﬁcally engineered restrictionsitebetween the env stopcodonand the
nef start codon) andXhoI. The env/LucR/T2A/nefDNA fragmentwas then
subcloned into theparental pNL4-3 genomeusingnative viral sites BamHI
(NL4-3 nt 8465) and XhoI (NL4-3 nt 8887). Sequence analysis conﬁrmed
all nucleotides were correct. The resulting proviral plasmid was named
pNL–LucR.T2A.
A panel of heterologous env ectodomain containing viruses were
constructed with functional env sequences from the R5-tropic viruses
BaL (GenBank ID: AY426110) and SF162 (GenBank ID: EU123924) and
the clade B transmitted envs from patients WITO4160, 700010040,
700010058, 700010077 (referred to as CH040, CH058 and CH077,
respectively) andWEAU0575 (Keele et al., 2008). The env ectodomains
were ampliﬁed with sense primers that anneal upstream of the native
viral KpnI sites (NL4-3 nt 6343), and antisense primers to insert a silent
BstBI site in themembrane-spanningdomains (MSD). Utilizing the KpnI
and BstBI sites, the env ectodomain fragments were then inserted into
the shuttle vector pSP72.mss, designed with the viral EcoRI (NL4-3 nt
5743) to XhoI (NL4-3 nt 8887) fragment from pNL4-3 with the unique
silent BstBI site introduced at nt 8301–8306 in the MSD coding region.
The heterologous ectodomain-encoding fragments were then trans-
ferred into the pNL4-3 backboneutilizing the EcoRI (NL4-3 nt 5743) and
BamHI (NL4-3nt 8465) sites to generate pNL–BaL.ecto, pNL–SF162.ecto,
pNL–WEAU.ecto, pNL–WITO.ecto, pNL–CH040.ecto, pNL–CH058.ecto
and pNL–CH077.ecto. The same EcoRI to BamHI fragments were
inserted into the pNL–LucR.T2A background, generating pNL–LucR.
T2A–BaL.ecto, pNL–LucR.T2A–SF162.ecto, pNL–LucR.T2A–WEAU.ecto,
pNL–LucR.T2A–WITO.ecto, pNL–LucR.T2A–CH040.ecto, pNL–LucR.T2A–
CH058.ecto and pNL–LucR.T2A–CH077.ecto. Sequence analysis con-
ﬁrmed all nucleotides were correct. The NL–LucR–T2A and NL–LucR.
T2A.Env.ecto constructs are collectively referred to as Env–IMC–LucR
reporter viruses.
Generation of virus stocks and determination of virus infectivity
293Tderivedvirus stocksweregeneratedbyproviralDNAtransfection
using FuGENE 6 according to themanufacturer's protocol (Roche Applied
Science). Viral supernatants were harvested 60 h post-transfection,
clariﬁed at 1800×g for 10 min, ﬁltered through 0.45 μm pore size ﬁlter
and frozen at−70 °C. The clariﬁed supernatants were analyzed for HIV-1
p24 antigen concentration by enzyme-linked immunosorbent assay
(ELISA) (Perkin-Elmer). Virus stocks were also titered on the TZM-bl
reporter cell line by enumeration of β-galactosidase (β-gal) stained
colonies as describedpreviously (Wei et al., 2002). The titeredvirus stocks
were further analyzed for infectivity and LucR gene expression in the
TZM-bl cell line. Brieﬂy, 96-well plates were seeded at a density of
2×104 cells per well one day prior to infection. The virus was diluted to
concentrations of 2×105, 2×104, 2×103 and 2×102 TZM-bl infectious
units (IU) perwell (MOI ranging from10 to 0.01) and added to the cells in
the presence of DEAE-Dextran (40 μg/mL) for 4 h at 37 °C. After the 4 h
incubationperiod, theviruswas removedand freshmediumwasadded to
11T.G. Edmonds et al. / Virology 408 (2010) 1–13the cells for an additional incubation of 48 h. The cells were then washed
oncewith PBS containingCa++andMg++, lysedwith 100 μL 1×Renilla
luciferase assay lysis buffer (Promega catalog no. E2820) and frozen at
−70 °C. Sampleswere freeze/thawed2 times and 20 μL of each cell lysate
were analyzed for both ﬁreﬂy (Promega catalog no. E1501) and LucR
activity. Samples were analyzed using a Victor 3 Luminometer (Perkin-
Elmer) programmed to inject 100 μL of Luciferase Assay Reagent per well
with an exposure time of 10 s/well, and reporting relative light units
(RLU)/s.
Western blot analysis
Provirally transfected 293T cells were washed with PBS and lysed
with Sample Buffer, Laemmli 2× Concentrate (Sigma-Aldrich), 48 h
post-transfection. Lysates were heated for 10 min at 95 °C and frozen
at −20 °C until use. Before use, samples were reheated at 95 °C for
10 min and the proteins resolved on a denaturing SDS-polyacrylamide
gel. Proteins were transferred to a nitrocellulose membrane, blocked
with 10% non-fat dried milk in Tris-buffered saline and reacted with
the appropriate primary antibodies to Renilla luciferase, HIV-1 Nef or
Gag proteins. The membranes were probed with either anti-mouse or
anti-rabbit horseradish peroxidase conjugated secondary antibodies
and analyzed by enhanced chemiluminescence.
Replication kinetics
2×106 PHA-P stimulatedPBMCwere infectedwith5×103 TZM-bl IU
(MOI of 0.0025) of virus in a 24-well plate for 4 h. The cells were then
washed twice with medium, resuspended in 5 mL of RPMI 1640
containing IL-2 (30 U/mL) and transferred to a T25ﬂask for theduration
of the experiment. Supernatantswere collected from the cultures on the
indicated sample days and stored at −70 °C until samples were
collectively analyzed by p24 ELISA. Medium removed for sampling
was replenished and midway through the experiment half of the
supernatant was replaced with fresh growth medium containing IL-2.
Determination of LucR stability
5×103 TZM-bl IU of 293T transfection-derived (TD) virus stocks
were used to infect 1.5–2×106 PHA-P stimulated PBMC(MOI of 0.0025)
in a 24-well plate for 4 h. The cells were then washed twice with fresh
medium, resuspended, and cultured in 5 mLof RPMI1640 containing IL-
2 (30 U/mL) for 14 days. Supernatants were collected from the cultures
over time, clariﬁed by centrifugation and frozen at−70 °C. The amount
of supernatant collected on each sample day was replaced with fresh
medium. Additionally, the cultures were fed with fresh uninfected cells
on day 10 (NL–LucR.T2A–BaL.ecto) or day 6 (NL–LucR.T2A–SF162.ecto).
The collected supernatants from days 6, 9 and 14, as well as the
cryopreserved transfection-derived stocks, were then used to infect
TZM-bl cells for the analysis of both cell-encoded ﬁreﬂy and virally-
encoded LucR. Brieﬂy, TZM-bl cells were plated one day prior to
infection at 1×104 cells per well in a 96-well plate. The next day, 5, 1, or
0.2 μL of cell-free PBMC supernatant from the determined time points
were added to each well, in triplicate, in the presence of DEAE-Dextran
(40 μg/mL) for 4 h. Transfection-derived virus stocks were analyzed in
parallel to the PBMC supernatants to determine a baseline stability ratio
of Renilla to ﬁreﬂy luciferase. After the 4 h incubation, the media were
replacedwith freshmedia and the samples incubated for 18 h. After the
incubation period, the reverse transcriptase inhibitor NVP (5 μM) was
added to the cultures to ensure a strictly single-round infection assay.
The cellswere cultured for an additional 18 h, then lysedwith 1×Renilla
luciferase lysis buffer and analyzed for both Renilla and ﬁreﬂy luciferase
activity. Fireﬂy luciferase activity served as a measure of overall
infectivity. The stability of the LucR gene in the viral genome was
assessed based on the ratio of the LucR to ﬁreﬂy luciferase expression at
different culture intervals.Neutralization
Inhibition of HIV-1 infectionwas analyzed in the TZM-bl cell line, the
NOMI reporter T-cell line and PBMC. TZM-bl cells were seeded 1 day
prior to infection in 96-well plates at a density of 1×104 cells/well in
complete DMEM media. On the day of infection, 2.5×103 TZM-bl IU of
the appropriate virus were incubated with inhibitors diluted to ﬁnal
concentrations of 25, 5, 1, 0.2, 0.04 and 0.008 μg/mL for 1 h at 37 °C. The
virus/inhibitormixturewas then transferred to thepre-seeded cells and
incubated for 48 h inmedia containingDEAE-Dextran (40 μg/mL). After
the incubation, the supernatant was removed and 100 μL of 1× Renilla
luciferase assay lysis buffer was added to each well and the samples
analyzed for both Renilla and ﬁreﬂy luciferase as described above. To
analyze HIV-1 neutralization in NOMI cells, 3×104 TZM-bl IU of the
appropriate virus were added to each well of a 96-well round bottom
plate and incubated for 1 h at 37 °C with inhibitors prepared as
described above. The virus/inhibitor mixture was then transferred to
2×105 NOMI cells in a 96-well round bottom plate and the samples
were incubated for 48 h at 37 °C. At the end of the incubation, 50 μL of
5× Renilla luciferase assay lysis buffer were added directly to each well.
Then, 20 μL of each cell lysate were analyzed for LucR activity as
described above. A protocol similar to the one used in the NOMI assay
was utilized to analyze HIV-1 neutralization in a two-day PBMC assay.
The only difference was the amount of virus (6.25×104 TZM-bl IU) and
the number of cells (1×105 PHA-P stimulated PBMC) per well. To
analyze HIV-1 neutralization in PBMC in a four-day assay, inhibitors
were ﬁrst diluted into 96-well plates. MAbs and HIVIG were diluted
three-fold, starting from a concentration of 25 μg/mL and 2500 μg/mL,
respectively. Plasma samples were initially diluted 1:20, followed by
seven 3-fold serial dilutions. Next, each virus was added at a
concentration that yielded relative light units (RLU) of at least 10
times above background and showed low exponential phase infection
after 4 days, and the virus/inhibitor mixture was incubated for 1 h at
37 °C. Then, 2–5×106 PBMC were added to each well and the cultures
were incubated for 4 days. At the end of the incubation, 75 μL of cell
suspension were transferred to a white solid plate and 30 μL of diluted
VivaRen Renilla luciferase substrate (Promega catalog no. E6495) was
added to each well (diluted 10 μL of Renilla Luciferase substrate into
3.5 mL of RPMI (without FBS) for each plate). The plates were read after
4 minbyusinganexposure of 0.5 s/well (Victor 3 Luminometer, Perkin-
Elmer). Percent neutralization was calculated by subtracting the
averaged cell control values (cells only) from the averaged sample
wells (cells+inhibitor+virus) and dividing this number by the
difference in the averaged positive control values (cells+virus) and
the averaged cell control values, subtracting this number from 1 and
multiplying by 100. Neutralizing titers of patient plasma are expressed
as the reciprocal of the plasma dilution required to reduce RLU by 50%.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.virol.2010.08.028.Acknowledgments
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